MOESM1 of Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer

Additional file 1: Figure S1. PC-9 and PC-9/PEM do not express FGFR1 or FGFR4 proteins. Figure S2 PD173074 sensitized PC-9/PEM to erlotinib but BLU-554 and nintedanib did not. Figure S3. Representative pictures and body weights of xenografts. Figure S4. Establishment of erlotinib-resistant NSCLC cell lines. Figure S5. Sequence alignment between PTK2 (Y407 to F729) and FGFR1 (Y463 to L819). Table S1. The sequences for primers used in RT- qPCR.